Maynard Um
-
-
-
-
-
-
-
Roivant Sciences (ROIV) Reiterated at Overweight by Cantor Fitzgerald After AAD Presentation
-
-
-
-
-
-
-
Roivant's Genevant and Arbutus reach $2.25 billion settlement with Moderna
-
-
-
-
-
-
-
Leerink on Roivant Sciences (ROIV): 'We expect brepocitinib’s Ph2 cutaneous sarcoidosis (CS) trial to deliver compelling efficacy in 1H26'
-
-
-
-
-
-
-
Roivant Sciences (ROIV) PT Raised to $26 at Citi
-
-
-
-
-
-
-
Roivant Sciences (ROIV) PT Raised to $20 at H.C. Wainwright
-
-
-
-
-
-
-
TD Cowen on Roivant Sciences (ROIV): 'We Like the Risk/Reward Profile of the Stock'
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Roivant Sciences (ROIV)
-
418,491 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

